
|Articles|November 12, 2020
Pipeline: New therapies to come for debilitating eye diseases
New drug from Gensight Biologics hits pipeline
Advertisement
GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.
Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2025: Comparing dry eye drops for patient comfort, adverse effects
2
AAOpt 2025: Perfluorohexyloctane use in patients with DED undergoing cataract surgery
3
AAOpt 2025: Multi-country real-world evaluation of a custom scleral lens system
4
AAOpt 2025: Diabetes case studies with an eye to the future with Dr Paul Chous
5